RxDoctor Payments Data

Shyam Bhaskar, MD

Internal Medicine · Visalia, CANPI 1194788158

Payments from drug & device makers

$6,200in general payments, 2019–2025

Across 430 payments — averaging $14.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$821
  • Novo Nordisk$810
  • Boehringer Ingelheim$499
  • Amgen$348
  • Pfizer$239
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$6,15199%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,200 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$405,080
Medicare patients
1,011
Services billed
5,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide377$381,808
JanuviaSitagliptin Phosphate271$248,426
FarxigaDapagliflozin Propanediol238$212,238
EliquisApixaban197$206,301
JardianceEmpagliflozin154$134,430
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf19$87,955
TradjentaLinagliptin85$59,942
LinzessLinaclotide46$45,967
RybelsusSemaglutide39$44,610
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$41,573
XareltoRivaroxaban45$40,877
Tresiba Flextouch U-100Insulin Degludec57$39,566
MounjaroTirzepatide33$38,651
Tresiba Flextouch U-200Insulin Degludec64$37,764
Repatha SureclickEvolocumab55$35,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$810$426,418416 claims
MerckJanuvia$186$248,426271 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Lokelma$1,048$246,096289 claims
PfizerEliquis$239$206,301197 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$499$203,024256 claims
GSKTrelegy Ellipta, Breo Ellipta$196$64,981101 claims
Lilly USA, LLCMounjaro, Trulicity$821$58,02645 claims
AbbVieLinzess, Savella$223$51,92758 claims
Johnson & JohnsonXarelto$52$40,87745 claims
NovartisEntresto$19$17,24518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →